Number of drugs used in secondary cardiovascular prevention and late survival in the population of Valencia Community, Spain

2019 ◽  
Vol 293 ◽  
pp. 260-265
Author(s):  
Josep Redón ◽  
Ruth Usó ◽  
Jose Luis Trillo ◽  
Cristina López ◽  
Francisco Morales-Olivas ◽  
...  
Keyword(s):  
Cardiovascular Prevention ◽  
Late Survival ◽  
Secondary Cardiovascular Prevention

Gender related differences in treatment and response to statins in primary and secondary cardiovascular prevention: The never-ending debate

2017 ◽  
Vol 117 ◽  
pp. 148-155 ◽  
Author(s):  
Roberto Cangemi ◽  
Giulio Francesco Romiti ◽  
Giuseppe Campolongo ◽  
Eleonora Ruscio ◽  
Susanna Sciomer ◽  
...  
Keyword(s):  
Cardiovascular Prevention ◽  
Secondary Cardiovascular Prevention

Risk of misclassification with a non-fasting lipid profile in secondary cardiovascular prevention

2017 ◽  
Vol 472 ◽  
pp. 90-95 ◽  
Author(s):  
Boudewijn Klop ◽  
Simone C.C. Hartong ◽  
Henricus J. Vermeer ◽  
Mariette W.C.J. Schoofs ◽  
Marcel J.M. Kofflard
Keyword(s):  
Lipid Profile ◽  
Cardiovascular Prevention ◽  
Secondary Cardiovascular Prevention ◽  
Risk Of Misclassification

scholarly journals Statins, an important tool in primary and secondary cardiovascular prevention

2016 ◽  
Vol 63 (1) ◽  
pp. 12-16
Author(s):  
Radu-Valentin Coltuc ◽  
◽  
Mihai Cezar Popescu ◽  
Victor Stoica ◽  
◽  
...  
Keyword(s):  
Cardiovascular Prevention ◽  
First Line ◽  
Good Tolerability ◽  
Important Place ◽  
Reductase Inhibitors ◽  
Cerebrovascular Events ◽  
Increased Risk ◽  
Hmg Coa Reductase Inhibitors ◽  
Coa Reductase ◽  
Secondary Cardiovascular Prevention

Among the major cardiovascular risk factors an important place is occupied by dyslipidemia. There is clear evidence that increased serum total cholesterol and low density fraction of cholesterol (LDLc) are associated with increased risk of coronary and cerebrovascular events. The therapeutic intervention on hyperlipidemia improves cardiovascular morbi-mortality. The most important class of drugs used in the last three decades to lower cholesterol is represented by HMG-CoA reductase inhibitors, generically called statins. Their benefit, regarding cardiovascular diseases, has been proven both in primary and in the secondary prevention. With a good tolerability and a good safety profile, statins remain the first line choice in dyslipidemic and even in normolipidemic patients, but with an increased risk of cardiovascular events.

scholarly journals Lovastatin: a new “ancient” molecule for hypercholesterolaemia/dyslipidaemia treatment

2008 ◽  
Vol 2 (2) ◽  
pp. 63-74
Author(s):  
Gianlorenzo Imperiale ◽  
Claudio Marengo
Keyword(s):  
Reductase Inhibitor ◽  
Cardiovascular Prevention ◽  
Lipid Lowering ◽  
Eligibility Criteria ◽  
Italian National Health Service ◽  
Clinical Benefits ◽  
Italian National Health ◽  
Hmgcoa Reductase Inhibitor ◽  
Secondary Cardiovascular Prevention

Lovastatin is the first HMGCoA-reductase inhibitor used for the control of hypercholesterolaemia (USA, 1987). In Italy, it’s been authorized for the therapy of hypercholesterolaemia/dyslipidaemia since end 2005. Several studies, conducted both in primary and in secondary cardiovascular prevention, underline the favourable profile in reducing the risk for ischaemic events and their complications. This molecule has the capability to reduce plasmatic atherogenic lipids levels enough to induce clinical benefits. The safety and tolerability of lovastatin are proved even for high dosages, as well as for long term use. Pharmacoeconomic evaluations have shown the value of its choice, in particular for patients who need lipid-lowering treatment but don’t satisfy eligibility criteria for reimbursement by the Italian National Health Service, as outlined by AIFA in 2005.

Sign in / Sign up

Export Citation Format

Share Document